Effect of osteoprotegerin on nitric oxide production and endothelial nitric oxide synthase activity in osteoclasts

doi:10.3969/j.issn.2095-4344.2014.42.001

Abstract

Abstract:

BACKGROUND: Osteoprotegerin and nitrogen monoxidum play a key role in the prevention and treatment of osteoporosis. However, the correlation of the two in inhibiting the proliferation and differentiation of osteoclasts remains unclear.
OBJECTIVE: To observe the effect of different doses of osteoprotegerin on nitric oxide production and endothelial nitric oxide synthase activity in osteoclasts.
METHODS: Tartrate resistant acid phophatase staining was used to test whether the induced cells are osteoclasts. Osteoclasts were divided into six groups: blank control group (no reagent); negative control group (DMEM); four osteoprotegerin groups (10, 25, 50, 75 μg/L of osteoprotegerin). Annexinv-FITC kit and flow cytometry were used to test the apoptosis rate of osteoclasts. Real-time PCR was used to detect the expression
of osteoclasts marker gene, TRAP mRNA and protein kinase K mRNA. Nitric oxide production and nitric oxide synthase activity were determined using the corresponding kits. Four osteoprotegerin groups were added with L-NAME, a kind of nitric oxide synthase inhibitor, to test the changes of the apoptosis rates of osteoclasts and the changes of the expression of TRAP mRNA and protein kinase K mRNA of osteoclasts.
RESULTS AND CONCLUSION: Osteoprotegerin inhibited the differentiation of osteoclasts and induced the apoptosis. Osteoprotegerin concentration had a positive correlation with the apoptosis rate of osteoclasts, and a negative correlation with the numbers of osteoclasts and expression of marker gene TRAP mRNA and protein kinase K mRNA in osteoclasts. Osteoprotegerin boosted the nitric oxide production and endothelial nitric oxide synthase activity, and osteoprotegerin concentration was positively correlated to the nitric oxide production and endothelial nitric oxide synthase activity. After Raw264.7 cells were in vitro cultured, osteoprotegerin and nitric oxide play a synergic role in inhibiting osteoclasts production and promoting the apoptosis. We speculate that there is osteoprotegerin/endothelial nitric oxide synthase/nitric oxide signal pathway.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: osteoprotegerin, osteoclasts, protein kinases

CLC Number:

R318

Zhao Shuai, He Ai-yong, Tao Cheng . Effect of osteoprotegerin on nitric oxide production and endothelial nitric oxide synthase activity in osteoclasts[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(42): 6725-6731.

Figures/Tables 7

References

[1] Simonet WS, Lacey DL, Dunstan CR, et al.Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell.1997;89(2): 309-319.
[2] 杨佳伟,饶利亚,毛奕,等,骨保护素不同层面对内皮细胞的影响[J]. 心脏杂志,2013(6): 649-653.
[3] 付应霄,顾建红,赵鸿雁,等,骨保护素对破骨细胞活性的影响[J].中国兽医学报,2013,33(5):738-741.
[4] Wang QP, Li XP, Wang M,et al.Adiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: an in ivo study. Endocrine. 2014 Mar 14. [E pub ahead of print].
[5] Inanc M, Kaynar L, Enhos S, et al.Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid. Med Oncol.2014;31(3):837.
[6] Wang B, Jin H, Zhu M,et al.Chondrocyte beta-catenin signaling regulates postnatal bone remodeling through modulation of osteoclast formation in a murine model. Arthritis Rheumatol. 2014; 66(1):107-120.
[7] Klein-Nulend J, van Oers RF, Bakker AD,et al.Nitric oxide signaling in mechanical adaptation of bone. Osteoporos Int. 2014;25(5):1427-1437.
[8] Buso G, Faggin E, Pauletto P, et al.Osteoprotegerin in Cardiovascular Disease:Ally or Enemy? Curr Pharm Des. 2014 Feb 12. [Epub ahead of print].
[9] Kitaura H, Kimura K, Ishida M,et al.Effect of cytokines on osteoclast formation and bone resorption during mechanical force loading of the periodontal membrane. Scientific World J. 2014;2014:617032.
[10] Wimalawansa SJ.Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. Ann N Y Acad Sci. 2007;1117: 283-297.
[11] Park EJ, Shen L, Sun D, et al.Inhibitory Effect of a Callophycin A Derivative on iNOS Expression via Inhibition of Akt in Lipopolysaccharide-Stimulated RAW 264.7 Cells. J Nat Prod. 2013. [Epub ahead of print]
[12] 杨伟,李裕舒,段卡丹,等.骨保护素对脐静脉内皮细胞生长的影响[J].临床心血管病杂志,2010,26(4):307-310.
[13] Hakimi M, Hyhlik-Dürr A, von Au A, et al.The expression of glycophorin A and osteoprotegerin is locally increased in carotid atherosclerotic lesions of symptomatic compared to asymptomatic patients. Int J Mol Med.2013;32(2):331-338.
[14] Park YJ, Shin YJ, Kim WU, et al.Prediction of subclinical atherosclerosis by serum osteoprotegerin in premenopausal women with systemic lupus erythematous: correlation of osteoprotegerin with monocyte chemotactic protein-1. Lupus. 2014; 23(3): 236-244.
[15] Augoulea A, Vrachnis N, Lambrinoudaki I, et al.Osteoprotegerin as a marker of atherosclerosis in diabetic patients. Int J Endocrinol. 2013;2013:182060.
[16] 肖本熙,张燕军,王端,等.白藜芦醇对去卵巢大鼠腰椎骨密度及NO、NOS影响[J].中国公共卫生，2014,05:632-634
[17] 张世旭.不同剂量L-arg对大鼠骨质疏松骨折骨愈合及血清NO、NOS的影响[D].太原:山西医科大学,2013.
[18] Joshua J, Kalyanaraman H, Marathe N, et al. Nitric oxide as a mediator of estrogen effects in osteocytes. Vitam Horm. 2014; 96:247-263.